Fibrin glue versus sutures for attaching the conjunctival autograft in pterygium surgery: a prospective observer masked clinical trial

S Srinivasan, M Dollin, P McAllum, Y Berger, D S Rootman, A R Slomovic

ABSTRACT
Aims: To compare the degree of conjunctival autograft inflammation, subconjunctival haemorrhage (SCH) and graft stability following the use of sutures or fibrin glue (FG) during pterygium surgery.

Methods: Prospective, observer masked, clinical trial. 40 eyes of 40 patients undergoing primary pterygium surgery with conjunctival autograft were allocated into two groups. Group 1 (n = 20) had FG (Tisseel) for attaching the conjunctival autograft, whereas group 2 (n = 20) had sutures. Standardised digital slit-lamp photographs were taken at 1 week, 1 month and 3 months postoperatively. Sutures were masked using commercially available photo-editing software. Two masked observers objectively graded the digital photographs for degree of inflammation, SCH and graft stability.

Results: 34 of the 40 patients completed the study. When using FG, the degree of inflammation was significantly less than with sutures at 1 month (p = 0.019) and 3 months (p = 0.001) postoperatively. No significant difference was found for inflammation at 1 week postoperatively (p = 0.518). Conjunctival grafts secured with FG were as stable as those secured with sutures (p = 0.258, p = 0.076 and p = 0.624, at 1 week, 1 month and 3 months, respectively). No significant difference was found in degree of postoperative SCH between the groups (p = 0.417, p = 1 and p = 1, at 1 week, 1 month and 3 months, respectively).

Conclusion: This is the first prospective clinical trial confirming that conjunctival grafts secured with FG during pterygium surgery not only are as stable as those secured with sutures, but also produce significantly less inflammation.

MATERIALS AND METHODS
Study population
Between October 2005 and January 2006, from a continuous cohort of 55 patients with primary pterygium referred to the Corneal Service at the Toronto Western Hospital, Toronto, 40 subjects were recruited to undergo primary pterygium excision with conjunctival autograft using FG or 10-0 polyglactin (vicryl) sutures. Institutional review board approval was obtained through the Toronto Academic Health Sciences Network/University Health Network Research Ethics Board, Toronto, Canada. The surgical procedures complied with the tenets of the Declaration of Helsinki. Inclusion criteria were a primary nasal pterygium, for which surgery was recommended, and willingness to participate in the clinical study. Exclusion criteria were subjects on anticoagulants, and recurrent or temporal location of pterygium. All patients gave written informed consent to participate in the study.

Surgical procedure
The surgical procedures were performed by two surgeons (SS and PM). The surgical procedures for subjects in group 1 (FG group, n = 20) were...
performed by SS, while PM performed the procedures for subjects in group 2 (suture group, n = 20). The surgical steps and procedures were standardised between the surgeons, with the only difference being the use of sutures or FG for attaching the conjunctival autograft. The procedure was carried out under a combination of topical (Proparacaine 0.5%, Alcaine, Alcon Canada, Mississauga, Canada) and subconjunctival (Xylocaine 2% with 1:100 000 epinephrine, AstraZeneca Canada, Mississauga, Canada) anaesthetic. All procedures were performed using an operating microscope. Under aseptic conditions, following the insertion of a Liebermann lid speculum, the body of the pterygium was marked using a sterile skin marker, and 0.1 ml of Xylocaine 2% with epinephrine was injected into the pterygium body. A 64 Beaver blade was used to excise the pterygium head from the cornea, and the body of the pterygium along with the underlying tenons was excised using Westcott scissors. A motorised diamond burr was used to smooth the corneal bed. Haemostasis of the scleral bed was achieved with a wet field cautery.

The area of the conjunctival defect was measured with a caliper, and a free conjunctival-limbal autograft measuring the same size as the conjunctival defect was obtained from the superotemporal quadrant of the bulbar conjunctiva. Westcott scissors and Fechtner conjunctival forceps were used to harvest the free conjunctival-limbal autograft. Meticulous dissection was performed to remove most of the tenons tissue in the autograft. The graft was moved over to the area of the conjunctival defect, with care taken to maintain the limbus to limbus and stromal side down orientation. At this stage, depending on the group in which the patients were allocated to, the autograft was secured either with multiple interrupted 10-0 polyglactin sutures or with FG (Tisseel). For subjects in group 1 (FG group, n = 20), the graft was placed on the cornea with the stromal side facing upwards. Three drops of the sealant protein and the sealant setting solution mounted on two separate syringes on a Duploject injection system were then placed on the scleral bed, and the conjunctival graft was immediately flipped over the area of conjunctival defect. The graft was quickly smoothed out with a non-toothed forceps while the thrombin was breaking down the fibrinopeptides to form fibrin clots. For subjects in group 2 (suture group, n = 20), multiple interrupted 10-0 polyglactin sutures were used to attach the autograft to the underlying episcleral bed. At the end of the procedure an antibiotic-steroid combination eye-drop, tobramycin–dexamethasone (TobraDex, Alcon Canada, Mississauga, Canada), was placed on all eyes, and all the eyes were patched.

**Patient evaluation and follow-up**

Postoperatively, subjects in both groups were treated with tobramycin–dexamethasone four times a day, which was gradually tapered over a period of 2 months. All subjects were seen at 1 day, 1 week, 1 month and 3 months postoperatively. During each postoperative visit, slit-lamp biomicroscopy and applanation tonometry were performed by any of three investigators (SS, PM, YB). Digital slit-lamp photography was performed during each postoperative visit (except on day 1) by the same three investigators (SS, PM, YB) using a Topcon slit lamp with Hitachi HV-C20MU camera (Topcon Corporation, Tokyo). A protocol was followed for obtaining digital slit-lamp photographs, which included the following: topical anaesthesia, lid speculum, and standardised light and magnification settings. The digital pictures obtained from the subjects in group 2 (suture group, n = 20) were imported into commercially available photo-editing software (Adobe Photoshop 7.0, Adobe Systems, San Jose, California). Using this software the visible sutures were masked in all the digital pictures by an independent clinician (MD). The digital pictures from both of the groups were then converted into a Tagged Image File Format (TIFF) file and randomly inserted as individual slides

**Table 1**  Scoring parameters for each of the three outcome variables

<table>
<thead>
<tr>
<th>Outcome variables</th>
<th>Scoring parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subconjunctival haemorrhage</td>
<td>Grade 0: None</td>
</tr>
<tr>
<td></td>
<td>Grade 1: 1 least 25% of the size of the graft</td>
</tr>
<tr>
<td></td>
<td>Grade 2: 1 least 50% of the size of the graft</td>
</tr>
<tr>
<td></td>
<td>Grade 3: 1 least 75% of the size of the graft</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Grade 0: No dilated corkscrew vessel in the graft</td>
</tr>
<tr>
<td></td>
<td>Grade 1: 1 bright red, dilated corkscrew vessel crossing the graft-bed margin</td>
</tr>
<tr>
<td></td>
<td>Grade 2: 2 bright red, dilated corkscrew vessels crossing the graft-bed margin</td>
</tr>
<tr>
<td></td>
<td>Grade 3: three bright red, dilated corkscrew vessels crossing the graft-bed margin</td>
</tr>
<tr>
<td>Graft stability</td>
<td>Grade 0: All four sides of the graft margin are well apposed</td>
</tr>
<tr>
<td></td>
<td>Grade 1: Gaping/displacement of one side of the graft-bed junction</td>
</tr>
<tr>
<td></td>
<td>Grade 2: Gaping/displacement of two sides of the graft-bed junction</td>
</tr>
<tr>
<td></td>
<td>Grade 3: Gaping/displacement of three sides of the graft-bed junction</td>
</tr>
<tr>
<td></td>
<td>Grade 4: Graft completely displaced from the bed</td>
</tr>
</tbody>
</table>

**Table 2**  Mann–Whitney U test results for each outcome variable at 1 week, 1 month and 3 months postoperatively

<table>
<thead>
<tr>
<th>Outcome variables</th>
<th>1 week postop</th>
<th>1 month postop</th>
<th>3 months postop</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tissel mean rank</td>
<td>Suture mean rank</td>
<td>p Value</td>
</tr>
<tr>
<td>Subconjunctival haemorrhage</td>
<td>18.82</td>
<td>16.18</td>
<td>0.417</td>
</tr>
<tr>
<td>Inflammation</td>
<td>16.44</td>
<td>18.56</td>
<td>0.518</td>
</tr>
<tr>
<td>Graft stability</td>
<td>19.18</td>
<td>15.82</td>
<td>0.258</td>
</tr>
</tbody>
</table>

Significant p values are highlighted in bold.
The conventional level of significance $p<0.05$ was applied in all cases.

**RESULTS**

The cohort consisted of 17 (42%) males. The mean age was 47 years (range 32 to 72). Thirty-four of the 40 patients completed the 3 months’ follow-up. The results are summarised in table 2.

The degree of inflammation was significantly less in the FG group at both 1 month ($p = 0.019$) and 3 months ($p = 0.001$) postoperatively (fig 1). There was no significant difference in the degree of inflammation between the groups at 1 week postoperatively ($p = 0.518$). Conjunctival graft stability with FG was the same as with sutures over the 3 months’ course of follow-up ($p = 0.258$, $p = 0.076$ and $p = 0.624$, at 1 week, 1 month and 3 months, respectively). There was no significant difference in the degree of SCH between the groups at any point during the follow-up period ($p = 0.417$, $p = 1$ and $p = 1$, at 1 week, 1 month and 3 months, respectively).

**DISCUSSION**

Pterygium recurrence is the most common complication of pterygium surgery and is a frequent source of frustration for patients and surgeons. With the aim of reducing recurrence rates, several surgical techniques have been described in the literature. These include bare sclera excision, conjunctival and conjunctival–limbal autograft, and the use of amniotic membrane. In addition, several adjunctive therapies, including the use of beta irradiation and mitomycin C (MMC), have been recommended due to their anti-fibrotic and anti-angiogenic properties.

From 1960 to the early 1980s, bare sclera closure was the most popular method for surgical removal of a primary pterygium. However, it has been shown that it is by far the least satisfactory method with respect to recurrence rates, which can be as high as 80%. The use of conjunctival autograft gained popularity in the 1980s following the landmark article by Kenyon et al in 1985. He reported a low recurrence rate of 5.3% using the conjunctival autograft technique. Since his publication, other prospective, randomised studies of conjunctival autografting during pterygium surgery have reported higher recurrence rates (16–39%) in high-risk populations.

Nonetheless, a recent detailed review on the treatment of pterygium concluded that conjunctival autograft remains the safest technique and offers the lowest rate of recurrence in the management of primary pterygium.

There is evidence that UV light-induced limbal stem-cell damage can act as a precursor to the development of pinguecula and pterygium. Thus, conceptually, one could possibly reduce pterygium recurrence rates by including the limbus in the harvested conjunctival autograft. Conjunctival–limbal autograft has been shown to be effective in the management of both primary and recurrent pterygia. There is very little scientific data on the preoperative morphological appearance, epidemiological status or surgical factors that influence pterygium recurrence rate. Tan et al in a prospective study were able to demonstrate that fleshiness of the pterygium is a significant risk factor for recurrence if bare sclera excision is performed.

Tisseel is a commercially available two-component fibrin sealant which mimics the natural fibrin and acts as tissue glue with sealing, haemostatic and gluing properties. The glue has two components: (1) sealant protein, a freeze-dried powder composed of human fibrinogen, fibrinonectin, plasminogen and Factor XIII reconstituted in a bovine aprotinin solution; (2) sealant setting, a solution composed of human thrombin reconstituted in a calcium chloride solution. When both of these solutions interact, through the action of thrombin, the fibrinopeptides are broken down to fibrin monomers. These monomers aggregate by cross-linking, leading to the formation of fibrin clot. Use of FG during pterygium surgery not only is safe and effective but also produces less postoperative pain when compared with the use of sutures.

Ti and Tseng demonstrated that increased inflammation during the postoperative period increases the risk of pterygium recurrence. Zuzuki et al showed that the use of silk and nylon sutures placed in the conjunctiva can cause inflammation, and migration of Langerhans’ cells to the cornea. In a large retrospective study, Koranyi et al were able to demonstrate a statistically significant decreased recurrence rate with the use of FG when compared with the use of sutures. They postulated that a possible reduction in the migration of fibroblast cells...
caused by the rapid adhesion of the graft with the FG may lead to decreased postoperative inflammation.

In our prospective, photo-documented, observer-masked clinical trial, we were able to demonstrate decreased postoperative inflammation (at both a 1-month and 3-month time gate) with the use of FG compared with polyglactin sutures. Although the aetiopathogenesis of pterygium recurrence may be multifactorial, we believe that reducing postoperative inflammation may play a significant role in reducing the recurrence rate. Larger, prospective studies are required to evaluate the long-term efficacy on the use of FG in reducing the recurrence rate.

Competing interests: None.

Ethics approval: Ethics approval was provided by the Toronto Academic Health Sciences Network/University Health Network Research Ethics Board, Toronto, Canada.

Patient consent: Obtained.

REFERENCES